Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000049598 | SCV000800701 | uncertain significance | Neuronal ceroid lipofuscinosis 1 | 2018-04-25 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000049598 | SCV001415148 | pathogenic | Neuronal ceroid lipofuscinosis 1 | 2024-01-29 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 91 of the PPT1 protein (p.Gln91Pro). This variant is present in population databases (rs386833639, gnomAD 0.02%). This missense change has been observed in individual(s) with neuronal ceroid lipofuscinosis (PMID: 17044973; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 56187). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PPT1 protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004700344 | SCV005202646 | uncertain significance | not specified | 2024-07-11 | criteria provided, single submitter | clinical testing | Variant summary: PPT1 c.272A>C (p.Gln91Pro) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 251460 control chromosomes. c.272A>C has been reported in the literature in the homozygous state in at least 1 individual affected with Neuronal Ceroid-Lipofuscinosis (Batten Disease) (example, Bi_2006). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication has been ascertained in the context of this evaluation (PMID: 17044973). ClinVar contains an entry for this variant (Variation ID: 56187). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. |
Juha Muilu Group; Institute for Molecular Medicine Finland |
RCV000049598 | SCV000082005 | probable-pathogenic | Neuronal ceroid lipofuscinosis 1 | no assertion criteria provided | not provided | Converted during submission to Likely pathogenic. | |
Natera, |
RCV000049598 | SCV002086004 | uncertain significance | Neuronal ceroid lipofuscinosis 1 | 2020-04-17 | no assertion criteria provided | clinical testing |